{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T19:50:20Z","timestamp":1792093820085,"version":"4.4.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T00:00:00Z","timestamp":1748217600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T00:00:00Z","timestamp":1748217600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Camurus AB"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1007\/s40262-025-01522-3","type":"journal-article","created":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T14:38:02Z","timestamp":1748270282000},"page":"1079-1092","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Population Pharmacokinetic Analysis of an Octreotide Depot (CAM2029) in the Treatment of Acromegaly"],"prefix":"10.1007","volume":"64","clinical-trial-number":[{"clinical-trial-number":"nct04076462","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04125836","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Ana\u00efs","family":"Glatard","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sofia","family":"Friberg-Hietala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lina","family":"Keutzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Hansson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Johnsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0080-4490","authenticated-orcid":false,"given":"Fredrik","family":"Tiberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,26]]},"reference":[{"issue":"3","key":"1522_CR1","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/1750-1172-3-17","volume":"25","author":"P Chanson","year":"2008","unstructured":"Chanson P, Salenave S. Acromegaly. Orphanet J Rare Dis. 2008;25(3):17.","journal-title":"Orphanet J Rare Dis"},{"issue":"2","key":"1522_CR2","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1530\/EJE-21-0216","volume":"185","author":"S Crisafulli","year":"2021","unstructured":"Crisafulli S, Luxi N, Sultana J, Fontana A, Spagnolo F, Giuffrida G, et al. Global epidemiology of acromegaly: a systematic review and meta-analysis. Eur J Endocrinol. 2021;185(2):251\u201363.","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"1522_CR3","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1007\/s11102-023-01360-1","volume":"27","author":"A Giustina","year":"2024","unstructured":"Giustina A, Biermasz N, Casanueva FF, Fleseriu M, Mortini P, Strasburger C, et al. Consensus on criteria for acromegaly diagnosis and remission. Pituitary. 2024;27(1):7\u201322.","journal-title":"Pituitary"},{"issue":"6","key":"1522_CR4","doi-asserted-by":"publisher","first-page":"630","DOI":"10.20945\/2359-3997000000193","volume":"63","author":"L Kasuki","year":"2019","unstructured":"Kasuki L, Rocha PDS, Lamback EB, Gadelha MR. Determinants of morbidities and mortality in acromegaly. Arch Endocrinol Metab. 2019;63(6):630\u20137.","journal-title":"Arch Endocrinol Metab."},{"issue":"2","key":"1522_CR5","first-page":"132","volume":"9","author":"K Gariani","year":"2013","unstructured":"Gariani K, Meyer P, Philippe J. Implications of somatostatin analogues in the treatment of acromegaly. Eur Endocrinol. 2013;9(2):132\u20135.","journal-title":"Eur Endocrinol."},{"issue":"3","key":"1522_CR6","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1016\/j.ghir.2010.02.003","volume":"20","author":"MJ Wassenaar","year":"2010","unstructured":"Wassenaar MJ, Biermasz NR, Kloppenburg M, van der Klaauw AA, Tiemensma J, Smit JW, et al. Clinical osteoarthritis predicts physical and psychological QoL in acromegaly patients. Growth Horm IGF Res. 2010;20(3):226\u201333.","journal-title":"Growth Horm IGF Res"},{"key":"1522_CR7","unstructured":"Electronic Medicines Compendium. Sandostatin 50 microgram\/1 ml, solution for injection\/infusion. 2021. https:\/\/www.medicines.org.uk\/emc\/product\/7822\/smpc. Accessed 10 Jul 2024."},{"issue":"1","key":"1522_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11102-020-01091-7","volume":"24","author":"M Fleseriu","year":"2021","unstructured":"Fleseriu M, Biller BMK, Freda PU, Gadelha MR, Giustina A, Katznelson L, et al. A Pituitary Society update to acromegaly management guidelines. Pituitary. 2021;24(1):1\u201313.","journal-title":"Pituitary"},{"issue":"4","key":"1522_CR9","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1208\/s12249-011-9693-z","volume":"12","author":"YS Rhee","year":"2011","unstructured":"Rhee YS, Sohn M, Woo BH, Thanoo BC, DeLuca PP, Mansour HM. Sustained-release delivery of octreotide from biodegradable polymeric microspheres. AAPS PharmSciTech. 2011;12(4):1293\u2013301.","journal-title":"AAPS PharmSciTech"},{"issue":"3","key":"1522_CR10","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1111\/bcp.12698","volume":"80","author":"F Tiberg","year":"2015","unstructured":"Tiberg F, Roberts J, Cervin C, Johnsson M, Sarp S, Tripathi AP, et al. Octreotide s.c. depot provides sustained octreotide bioavailability and similar IGF-1 suppression to octreotide LAR in healthy volunteers. Br J Clin Pharmacol. 2015;80(3):460\u201372.","journal-title":"Br J Clin Pharmacol"},{"issue":"2","key":"1522_CR11","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1007\/s12325-016-0472-9","volume":"34","author":"M Albayaty","year":"2017","unstructured":"Albayaty M, Linden M, Olsson H, Johnsson M, Strandg\u00e5rden K, Tiberg F. Pharmacokinetic evaluation of once-weekly and once-monthly buprenorphine subcutaneous injection depots (CAM2038) versus intravenous and sublingual buprenorphine in healthy volunteers under naltrexone blockade: an open-label phase 1 study. Adv Ther. 2017;34(2):560\u201375.","journal-title":"Adv Ther"},{"key":"1522_CR12","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/978-1-4614-0554-2_16","volume-title":"Long Acting Injections and Implants","author":"F Tiberg","year":"2012","unstructured":"Tiberg F, Johnsson M, Nistor C, Joabsson F. Self-Assembling Lipid Formulations. In: Wright JC, Burgess DJ, editors. Long Acting Injections and Implants. Boston, MA: Springer, US; 2012. p. 315\u201333."},{"key":"1522_CR13","unstructured":"National Institute for Health and Care Excellence. Octreotide. https:\/\/bnf.nice.org.uk\/drugs\/octreotide\/. Accessed 10 Jul 2024."},{"issue":"6","key":"1522_CR14","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.1210\/clinem\/dgae707","volume":"110","author":"D Ferone","year":"2025","unstructured":"Ferone D, Freda P, Katznelson L, Gatto F, Kadio\u011flu P, Maffei P, et al. Octreotide subcutaneous depot for acromegaly: a randomized, double-blind, placebo-controlled phase 3 trial, ACROINNOVA 1. J Clin Endocrinol Metab. 2024. https:\/\/doi.org\/10.1210\/clinem\/dgae707.","journal-title":"J Clin Endocrinol Metab"},{"issue":"10","key":"1522_CR15","doi-asserted-by":"publisher","first-page":"1578","DOI":"10.3390\/pharmaceutics13101578","volume":"13","author":"I Kapralos","year":"2021","unstructured":"Kapralos I, Dokoumetzidis A. Population pharmacokinetic modelling of the complex release kinetics of octreotide LAR: defining sub-populations by cluster analysis. Pharmaceutics. 2021;13(10):1578.","journal-title":"Pharmaceutics"},{"issue":"6","key":"1522_CR16","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1046\/j.1365-2125.2000.00297.x","volume":"50","author":"H Zhou","year":"2000","unstructured":"Zhou H, Chen TL, Marino M, Lau H, Miller T, Kalafsky G, et al. Population PK and PK\/PD modelling of microencapsulated octreotide acetate in healthy subjects. Br J Clin Pharmacol. 2000;50(6):543\u201352.","journal-title":"Br J Clin Pharmacol"},{"key":"1522_CR17","unstructured":"Beal S, Sheiner L, Boeckmann A, Bauer R. NONMEM 7.4 Users guides. (1989\u20132019). 2019. https:\/\/nonmem.iconplc.com\/nonmem744. Accessed 10 Jul 2024."},{"issue":"3","key":"1522_CR18","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.cmpb.2005.04.005","volume":"79","author":"L Lindbom","year":"2005","unstructured":"Lindbom L, Pihlgren P, Jonsson EN. PsN-Toolkit\u2014a collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM. Comput Methods Programs Biomed. 2005;79(3):241\u201357.","journal-title":"Comput Methods Programs Biomed"},{"issue":"2","key":"1522_CR19","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.cmpb.2003.11.003","volume":"75","author":"L Lindbom","year":"2004","unstructured":"Lindbom L, Ribbing J, Jonsson EN. Perl-speaks-NONMEM (PsN)\u2014a Perl module for NONMEM related programming. Comput Methods Programs Biomed. 2004;75(2):85\u201394.","journal-title":"Comput Methods Programs Biomed"},{"issue":"1","key":"1522_CR20","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/S0169-2607(98)00067-4","volume":"58","author":"EN Jonsson","year":"1999","unstructured":"Jonsson EN, Karlsson MO. Xpose\u2014an S-PLUS based population pharmacokinetic\/pharmacodynamic model building aid for NONMEM. Comput Methods Programs Biomed. 1999;58(1):51\u201364.","journal-title":"Comput Methods Programs Biomed"},{"key":"1522_CR21","unstructured":"Team RC. R: a language and environment for statistical computing. 2019. https:\/\/www.R-project.org. Accessed 10 Jul 2024."},{"key":"1522_CR22","unstructured":"Jonsson EN, Harling K. Increasing the efficiency of the covariate search algorithm in the SCM. PAGE. Montreux, Switzerland; 2018."},{"issue":"9","key":"1522_CR23","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1023\/A:1011970125687","volume":"15","author":"EN Jonsson","year":"1998","unstructured":"Jonsson EN, Karlsson MO. Automated covariate model building within NONMEM. Pharm Res. 1998;15(9):1463\u20138.","journal-title":"Pharm Res"},{"issue":"3","key":"1522_CR24","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1038\/clpt.2011.149","volume":"90","author":"D Menon-Andersen","year":"2011","unstructured":"Menon-Andersen D, Yu B, Madabushi R, Bhattaram V, Hao W, Uppoor RS, et al. Essential pharmacokinetic information for drug dosage decisions: a concise visual presentation in the drug label. Clin Pharmacol Ther. 2011;90(3):471\u20134.","journal-title":"Clin Pharmacol Ther"},{"issue":"2","key":"1522_CR25","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1208\/s12248-011-9255-z","volume":"13","author":"M Bergstrand","year":"2011","unstructured":"Bergstrand M, Hooker AC, Wallin JE, Karlsson MO. Prediction-corrected visual predictive checks for diagnosing nonlinear mixed-effects models. AAPS J. 2011;13(2):143\u201351.","journal-title":"AAPS J"},{"key":"1522_CR26","unstructured":"Karlsson M, Holford N. A Tutorial on visual predictive checks. PAGE. Marseille, France; 2008."},{"key":"1522_CR27","unstructured":"Baron KT. mrgsolve: simulate from ODE-based models. 2024. https:\/\/github.com\/metrumresearchgroup\/mrgsolve. Accessed 10 Jul 2024."},{"key":"1522_CR28","doi-asserted-by":"publisher","first-page":"65","DOI":"10.3109\/00365528609087433","volume":"119","author":"K Kutz","year":"1986","unstructured":"Kutz K, N\u00fcesch E, Rosenthaler J. Pharmacokinetics of SMS 201\u2013995 in healthy subjects. Scand J Gastroenterol Suppl. 1986;119:65\u201372.","journal-title":"Scand J Gastroenterol Suppl"},{"issue":"7","key":"1522_CR29","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1177\/0091270005277936","volume":"45","author":"B Astruc","year":"2005","unstructured":"Astruc B, Marbach P, Bouterfa H, Denot C, Safari M, Vitaliti A, et al. Long-acting octreotide and prolonged-release lanreotide formulations have different pharmacokinetic profiles. J Clin Pharmacol. 2005;45(7):836\u201344.","journal-title":"J Clin Pharmacol"}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-025-01522-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40262-025-01522-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-025-01522-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,23]],"date-time":"2025-06-23T14:56:35Z","timestamp":1750690595000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40262-025-01522-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,26]]},"references-count":29,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["1522"],"URL":"https:\/\/doi.org\/10.1007\/s40262-025-01522-3","relation":{},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"value":"0312-5963","type":"print"},{"value":"1179-1926","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,26]]},"assertion":[{"value":"28 April 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 May 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The trials and this analysis were funded by Camurus AB. Pharmacokinetic analysis by Pharmetheus AB was funded by Camurus AB. Support for third-party writing assistance for this article, provided by Melanie Seaton, PhD, and James Evry, MSc, Costello Medical, UK, was funded by Camurus AB in accordance with Good Publication Practice (GPP3) guidelines ().","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Anna Hansson, Markus Johnsson and Fredrik Tiberg are current employees of Camurus AB. Ana\u00efs Glatard and Lina Keutzer are employees of Pharmetheus, who were contracted to perform the analysis. Sofia Friberg-Hietala is an employee and co-owner of Pharmetheus.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"The authors will not make data collected for this analysis available to others.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"Ethics approval and informed consent of each trial participant were obtained before trial inclusion, as detailed previously in the primary publications from the three clinical trials or within the appropriate records on the EudraCT or ClinicalTrials.gov registries (registration numbers: 2020-002643-35, NCT04076462, NCT04125836). These three clinical trials, and the analysis detailed here, were\/are being conducted in accordance with Good Clinical Practice Guidelines and the ethical principles as laid down in the 1964 Declaration of Helsinki.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Oral and written informed consent to participate was obtained from all trial participants before enrolment in the trials.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"All the results presented in this article are in aggregate form, and no personally identifiable information was used for this analysis.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"Due to its proprietary nature, the authors will not make code available to others.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"Substantial contributions to analysis conception and design: AG, SFH, LK, AH, MJ and FT; substantial contributions to analysis and interpretation of the data: AG, SFH, LK, AH, MJ and FT; drafting the article or revising it critically for important intellectual content: AG, SFH, LK, AH, MJ and FT; final approval of the version of the article to be published: AG, SFH, LK, AH, MJ and FT.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 Contributions"}}]}}